- Home
- FTRE vs HTFL Comparison
FTRE vs HTFL Comparison
Compare FTRE & HTFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FTRE | HTFL |
|---|---|---|
| Founded | 1996 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.2B |
| IPO Year | 2023 | 2025 |
Fundamental Metrics
Financial Performance| Metric | FTRE | HTFL |
|---|---|---|
| Price | $21.51 | $51.24 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 10 |
| Target Price | $20.67 | ★ $46.00 |
| AVG Volume (30 Days) | 1.3M | ★ 1.4M |
| Earning Date | 10-29-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 82.37 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,723,400,000.00 | $176,034,000.00 |
| Revenue This Year | N/A | $41.41 |
| Revenue Next Year | $3.05 | $24.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 1.00 | ★ 39.92 |
| 52 Week Low | $8.55 | $20.13 |
| 52 Week High | $21.39 | $53.07 |
Technical Indicators
Market Signals| Indicator | FTRE | HTFL |
|---|---|---|
| Relative Strength Index (RSI) | 65.64 | 60.67 |
| Support Level | $15.94 | $46.44 |
| Resistance Level | N/A | $51.73 |
| Average True Range (ATR) | 1.08 | 2.43 |
| MACD | 0.14 | -0.28 |
| Stochastic Oscillator | 55.38 | 59.95 |
Price Performance
Historical ComparisonAbout FTRE Fortrea Holdings Inc.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.
About HTFL Heartflow Inc.
HeartFlow Inc is a commercial-stage medical technology company that provides software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease. The company operates and manages its business as a single reportable operating segment: non-invasive coronary artery disease detection solutions. Geographically, it operates in the United States and the rest of Europe, deriving the majority of its revenue from the United States. The company has developed three software products: Heartflow Roadmap Analysis, Heartflow FFRCT Analysis, and Heartflow Plaque Analysis.